Majors
101 IP cases indexed. Covers patent matters.
Cases Presided Over
101 cases indexed | Page 4 of 4
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable. Petitioner Imperative Care proved anticipation and obviousness over Schaffer, Hartley, Eller and Garrison, with the Board emphasizing that the claimed filament must be flexible.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on all nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB has instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All challenged claims (1‑8, 12‑19) are now subject to trial.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care proved all nine claims of Inari Medical’s 11,697,011 B2 hemostasis valve patent are unpatentable, finding the term “filament” must be flexible and that the prior art renders the claims obvious.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of unpatentability. The petition relied on anticipation and obviousness over Garrison and other references, but lacked sufficient particularity.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted Imperative Care’s petition to institute inter partes review of Inari Medical’s hemostasis‑valve patent, finding a reasonable likelihood of unpatentability for claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation by Schaffer and obviousness over combinations with Hartley, Eller and Garrison. The decision hinges on the Board’s construction that the claimed filament must be flexible, which the prior art does not disclose.
Valneva Austria GMBH v.Takeda Vaccines, Inc.
Valneva Austria and Takeda Vaccines jointly moved to terminate an IPR covering 67 vaccine‑related claims. The Board granted the motion, dismissing the petition without a merits decision.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering a vacuum aspiration system with hemostasis valve. Petitioner Imperative Care showed a reasonable likelihood of prevailing on at least one claim, especially claim 1, based on obviousness over Garrison, Schaffer and other references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent after Imperative Care demonstrated a reasonable likelihood of unpatentability on claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent, covering claims 1‑9, on grounds of anticipation and obviousness.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.